Evolving Treatment Paradigms in Endometrial Cancer

Experts in gynecologic cancer discuss the heterogeneity of endometrial cancer..

Key opinion leaders share their thoughts on biomarker testing and multidisciplinary approaches for endometrial cancer at their institutions globally.

Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.

Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.

Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.

Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.

Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.

Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.

Experts in endometrial cancer comment on therapeutic sequencing in endometrial cancer.

Experts discuss the importance of incorporating molecular features into the selection of adjuvant treatment.

Key opinion leaders take a look at the evolving treatment landscape in endometrial cancer, discussing ongoing trials in the space.

Experts in endometrial cancer comment on novel targets of interest that are currently being investigated.

Nicoletta Colombo, MD, PhD, reviews surgical advancements in endometrial cancer.

Experts give insight on what they are looking forward to in the endometrial cancer space.